Definium Therapeutics (DFTX) Interest Expenses (2023 - 2026)

Definium Therapeutics (DFTX) has 4 years of Interest Expenses data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Interest Expenses rose 99.34% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 148.8% YoY) and the FY2025 annual result came in at $5.5 million, up 140.91% from the prior year.
• Interest Expenses retreated to $1.2 million in Q1 2026 per DFTX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.3 million in Q2 2025 and bottomed at $51000.0 in Q3 2023.
• The 4-year median for Interest Expenses is $649000.0 (2023), against an average of $756615.4.
• Peak annual rise in Interest Expenses reached 1325.49% in 2024, while the deepest fall reached 1.08% in 2024.
• Tracing DFTX's Interest Expenses over 4 years: stood at $649000.0 in 2023, then climbed by 1.08% to $656000.0 in 2024, then jumped by 96.04% to $1.3 million in 2025, then decreased by 6.69% to $1.2 million in 2026.
• Per Business Quant, the three latest DFTX Interest Expenses figures stand at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025).

Peer Comparison